Get the Stockscreener App
5.38
2.09%
0.11
Savara Inc stock is traded at $5.38, with a volume of 1.65M.
It is up +2.09% in the last 24 hours and down -5.45% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.27
Open:
$5.25
24h Volume:
1.65M
Relative Volume:
0.94
Market Cap:
$1.11B
Revenue:
-
Net Income/Loss:
$-129.48M
P/E Ratio:
-9.6347
EPS:
-0.5584
Net Cash Flow:
$-106.97M
1W Performance:
-7.72%
1M Performance:
-5.45%
6M Performance:
-3.93%
1Y Performance:
+78.74%
1-Day Range:
$5.14
$5.40
1-Week Range:
$5.14
$5.98
52-Week Range:
$2.92
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.38 | 1.17B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - MarketBeat
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Savara (SVRA) Earnings Date and Reports 2026 - MarketBeat
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC - MarketBeat
Savara Inc (YB4P.SG) recent insider transactions - au.finance.yahoo.com
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 88.90% Potential Upside - directorstalkinterviews.com
Savara investors brace for earnings ahead of crucial FDA review By Investing.com - Investing.com Nigeria
Savara (SVRA) to Announce Quarterly Earnings on Wednesday - MarketBeat
SVRA Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA) - Seeking Alpha
Savara's upcoming APAP BLA filing seen as key c... - pluang.com
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - The National Law Review
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA - MarketBeat
Savara Inc. (SVRA) Gains 2% as Shares Test Key Resistance LevelsVolume Dry Up - dars.gov.et
Savara secures European, Australian patents for MOLBREEVI By Investing.com - Investing.com Nigeria
SVRA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Savara Inc. $SVRA Shares Bought by Eversept Partners LP - marketbeat.com
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Orbimed Advisors LLC Acquires Shares of 635,000 Savara Inc. $SVRA - MarketBeat
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc. (SVRA) Q1 2026 Earnings: Net Loss Widens on Higher R&D Spend, Stock DipsDiluted EPS Report - dars.gov.et
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA - TradingView
TradingKey - TradingKey
SVRA|Savara Inc|Price:5.510|Chg%:-0.240 - TradingKey
Affinity Asset Advisors LLC Decreases Stock Holdings in Savara Inc. $SVRA - MarketBeat
Form 4 Savara Inc For: 24 July By Investing.com - Investing.com Nigeria
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction - Kalkine Media
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs - Stock Titan
Savara Inc. (SVRA) Edges Lower as Stock Approaches Critical Support at $5.37Demand Zone - dars.gov.et
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Amidst Ongoing Clinical DevelopmentEarnings Revision Upgrade - dars.gov.et
ETFs Investing in Savara, Inc. Stocks - TradingView
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy - Ad-hoc-news.de
If You Invested $1,000 in Savara Inc (SVRA) - Stock Titan
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Here's Why You Should Add Savara Stock to Your Portfolio Now - Yahoo Finance
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):